//
Triple receptor agonist targeting GLP-1, GIP, and glucagon pathways
These products are intended for laboratory research use only and are not for human consumption. Not for use in food, drug, household, or cosmetic applications. All research should be conducted in accordance with applicable safety guidelines and regulations.
Retatrutide is a novel triple agonist that simultaneously engages GLP-1, GIP, and glucagon receptors within a single peptide molecule. This triple-receptor approach represents a significant advance in multi-pathway metabolic research, offering scientists a tool to study the convergence of incretin and glucagon signaling.
Phase 2 clinical data for retatrutide revealed substantial metabolic effects attributable to coordinated activation of three distinct receptor pathways, positioning it as a next-generation compound for metabolic research.
Price comparison based on publicly available data. Competitor prices may vary.
Store in refrigerator at 4°C, tightly sealed, away from heat, light and moisture.. Keep frozen until ready to reconstitute.
Use sterile water for injection. Allow to reach room temperature before reconstitution.
Stable for 24 months when stored properly. Once reconstituted, use within 30 days.